Novel Advances in Hereditary ATTR Amyloidosis: Payer and Specialty Pharmacy Considerations

Novel Advances in Hereditary ATTR Amyloidosis: Payer and Specialty Pharmacy Considerations is organized by Pharmacy Times Continuing Education (PTCE). 

Release Date: June 3, 2019
Expiration Date: June 3, 2020

Target Audience: 
Specialty Pharmacists and Managed Care Professionals.

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)

Program Description:
Amyloidosis refers to a heterogeneous group of multisystemic, debilitating, fatal disorders affecting normal tissue and organ structure and function due to amyloid fibril deposits in extracellular tissues. Hereditary transthyretin amyloidosis (hATTR) is one of these disorders and affects approximately 50,000 individuals worldwide. As the disease progresses, patients experience a myriad of symptoms that may include weight loss, gastrointestinal dysfunction, and polyneuropathy. The course of hATTR may be slowed with early diagnosis and treatment. Until recently, treatments have only helped to alleviate symptoms, but the treatment landscape has changed with the approval of 2 disease-modifying therapies in the United States that target the disease process at the cellular level. Due to its progressive nature, hATTR impacts patients and their caregivers, both of whom report a much reduced quality of life due to the physical, mental, and financial demands of the disease. Specialty pharmacists and payers must be familiar with current and emerging therapies for the treatment of hATTR to improve the clinical outcomes for patients with hATTR while managing health care resources.

Educational Objectives:
At the completion of this activity, the participant will be able to:
• Examine the pathophysiology of hATTR
• Explain the diagnostic challenges of hATTR
• Analyze data supporting the use of current and emerging therapies for the treatment of hATTR
• Identify approaches for payers to effectively manage ultra-rare diseases